

4 July 2022

Lung Cancer Pharma

Q1. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:

- Afatinib: <5
- Alectinib: <5
- Amivantamab: <5
- Atezolizumab monotherapy: 14
- Atezolizumab with chemotherapy: <5
- Brigatinib: <5
- Ceritinib: <5
- Crizotinib: <5
- Dacomitinib: <5
- Dabrafenib with Trametinib: <5
- Durvalumab: 25
- Erlotinib: <5
- Gefitinib: <5
- Lorlatinib: <5
- Mobocertinib: <5
- Nintedanib with Docetaxel: <5
- Nivolumab: <5
- Osimertinib: 34
- Pembrolizumab monotherapy: 63
- Pembrolizumab with chemotherapy: <5
- Pemetrexed with Carboplatin/Cisplatin: 18
- Pemetrexed with Carboplatin/Cisplatin + Pembrolizumab: 23
- Pemetrexed Maintenance: <5
- Sotorasib: <5
- Tepotinib: <5
- Vinorelbine with Carboplatin: 14 /Cisplatin: 8
- Any other active systemic anti-cancer therapy (SACT)
 - Cisplatin + Gemcitabine: <5
 - Docetaxel: 6
 - Gemcitabine + Carboplatin: 9
 - Nintedanib: <5
 - Paclitaxel + Carboplatin: 9
- Palliative care only

Use of < 5 (less than five): We are unable to provide an exact figure - exempt from release under section 40(2) of the FOI Act - as this could make patients personally

4 July 2022

identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulations 2018.

Q2. In the past 3 months, how many patients were treated for Squamous non-small cell lung cancer (Sq NSCLC) ONLY with the following drugs:

- Atezolizumab monotherapy
- Atezolizumab with chemotherapy
- Durvalumab
- Nivolumab
- Osimertinib
- Pembrolizumab (Keytruda) Mono
- Pembrolizumab (Keytruda) with Chemotherapy
- Tepotinib
- Other active systemic anti-cancer therapy (SACT)
- Palliative care only

Please note: Figures supplied are total figures from RISOH; we are unable to distinguish between NSCLC and Sq NSCLC